<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077777</url>
  </required_header>
  <id_info>
    <org_study_id>MES-CT 01</org_study_id>
    <nct_id>NCT02077777</nct_id>
  </id_info>
  <brief_title>Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an &quot;in Vivo&quot; Evaluation of the Molecular Effects on β-catenin Signaling Pathway.</brief_title>
  <official_title>Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari &quot;in Vivo&quot; Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOFAR S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOFAR S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain an &quot;in vivo&quot; confirmation that mesalazine induces the
      gene expression of μ-protocadherin and other related genes in the colon mucosa, as
      demonstrated in some &quot;in vitro&quot; experiments. .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot Trial, single-blind, parallel group on biopsy specimens of healthy colon mucosa in
      patients with precancerous lesions of the colon and rectum (adenomas) treated with
      mesalazine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular analysis of gene expression levels of μ-protocadherin and other related proteins</measure>
    <time_frame>3 months</time_frame>
    <description>Molecular analysis (quantitative RT-PCR) of gene expression levels of μ-protocadherin, protocadherin 19, protocadherin 24, cadherin E, TCF7L2, TCF4, c-myc, Cyclin D1, p21waf1, VEGF, CD44, Met, KLF4 e CEBP-α and comparison of the levels assessed at the end of the treatment period with the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid</measure>
    <time_frame>3 months</time_frame>
    <description>These parameters will be examined using molecular analysis of the oxidation and depurination levels of the DNA and chromatographic analysis of the intra-mucosal concentration of 5-Acetylsalicylic acid, in biopsies of normal mucosa of the colon taken before and after the treatment of patients with 5-Acetylsalicylic acid:
quantification of the percentage of cells expressing the following proteins by immunohistochemical analysis: μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ;
quantification of number of AP sites per 100000 DNA bp
quantification of nanograms di 8-OhdG (8-hydroxyguanine) per micrograms of DNA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>5-ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesalazine 800 mg orally t.i.d for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine</intervention_name>
    <description>Mesalazine cpr 800 mg t.i.d. for 3 months</description>
    <arm_group_label>5-ASA</arm_group_label>
    <other_name>5-aminosalicylic acid</other_name>
    <other_name>5-ASA</other_name>
    <other_name>Pentacol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with precancerous colorectal lesions (polypoid or nonpolypoid adenomas) that
             needs of an endoscopic exam of control after 3 months from the removal of the lesions
             (determined on the basis of the morphological and histological characteristics of the
             lesions and of the removal technique)

          -  Ability and willingness to adhere to study regimen

          -  Written informed consent

        The following inclusion criteria was deleted according to Amendment n. 01 approved by the
        Ethical Committee on 19/dec/2014:

        - diverticular disease/diverticular colitis;

        The rationale of this change is that the presence of diverticular disease/diverticular
        colitis does not contribute to the definition of the trial primary end-points and
        represents a critical point during the patient selection with an impact on duration and
        conduction of the study.

        Exclusion Criteria:

          -  Patients under therapy with Aspirin (&gt;100 mg/die) or other FANS

          -  Inflammatory bowel disease (IBD)

          -  Hypersensitivity to Mesalazine.

          -  Pregnant or nursing (lactating) women

          -  Patients who belonging to the category n. 4 of the ASA physical status classification
             system

          -  contraindications to mesalazine therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Buffoli, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituti Ospitalieri di Cremona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Parenti S, Ferrarini F, Zini R, Montanari M, Losi L, Canovi B, Ferrari S, Grande A. Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells. Aliment Pharmacol Ther. 2010 Jan;31(1):108-19. doi: 10.1111/j.1365-2036.2009.04149.x.</citation>
    <PMID>19785626</PMID>
  </reference>
  <reference>
    <citation>Losi L, Parenti S, Ferrarini F, Rivasi F, Gavioli M, Natalini G, Ferrari S, Grande A. Down-regulation of μ-protocadherin expression is a common event in colorectal carcinogenesis. Hum Pathol. 2011 Jul;42(7):960-71. doi: 10.1016/j.humpath.2010.10.009. Epub 2011 Mar 2.</citation>
    <PMID>21315419</PMID>
  </reference>
  <reference>
    <citation>Brown JB, Lee G, Managlia E, Grimm GR, Dirisina R, Goretsky T, Cheresh P, Blatner NR, Khazaie K, Yang GY, Li L, Barrett TA. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 2010 Feb;138(2):595-605, 605.e1-3. doi: 10.1053/j.gastro.2009.10.038. Epub 2009 Oct 29.</citation>
    <PMID>19879273</PMID>
  </reference>
  <reference>
    <citation>Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005 Jun;100(6):1345-53.</citation>
    <PMID>15929768</PMID>
  </reference>
  <reference>
    <citation>Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 2010 Jan 15;31(2):202-9. doi: 10.1111/j.1365-2036.2009.04195.x. Epub 2009 Nov 5. Review.</citation>
    <PMID>19891667</PMID>
  </reference>
  <reference>
    <citation>Gushima M, Hirahashi M, Matsumoto T, Fujita K, Fujisawa R, Mizumoto K, Nakabeppu Y, Iida M, Yao T, Tsuneyoshi M. Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated carcinogenesis. J Pathol. 2009 Sep;219(1):77-86. doi: 10.1002/path.2570.</citation>
    <PMID>19479711</PMID>
  </reference>
  <reference>
    <citation>Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B. Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis. 2010 Sep;25(5):463-71. doi: 10.1093/mutage/geq028. Epub 2010 Jun 9.</citation>
    <PMID>20534734</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesalazine</keyword>
  <keyword>colon</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
    <mesh_term>Aminosalicylic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

